

Policy: MPA G2151

Section: Medical Policy

Subject: Serum Testing for Evidence of Mild Traumatic Brain Injury

Applicable Lines of Business

Commercial	x	CHIP	x
Medicare	x	ACA	x
Medicaid	x		

I. Policy: Serum Testing for Evidence of Mild Traumatic Brain Injury

II. Purpose/Objective: To provide a policy of coverage regarding

III. Responsibility:
 A. Medical Directors
 B. Medical Management

IV. Required Definitions

1. Attachment – a supporting document that is developed and maintained by the policy writer or department requiring/authoring the policy.
2. Exhibit – a supporting document developed and maintained in a department other than the department requiring/authoring the policy.
3. Devised – the date the policy was implemented.
4. Revised – the date of every revision to the policy, including typographical and grammatical changes.
5. Reviewed – the date documenting the annual review if the policy has no revisions necessary.

Commercial

Geisinger Health Plan may refer collectively to health care coverage sponsors Geisinger Health Plan, Geisinger Quality Options, Inc., and Geisinger Indemnity Insurance Company, unless otherwise noted. Geisinger Health Plan is part of Geisinger, an integrated health care delivery and coverage organization.

Medicare

Geisinger Gold Medicare Advantage HMO, PPO, and HMO D-SNP plans are offered by Geisinger Health Plan/Geisinger Indemnity Insurance Company, health plans with a Medicare contract. Continued enrollment in Geisinger Gold depends on contract renewal. Geisinger Health Plan/Geisinger Indemnity Insurance Company are part of Geisinger, an integrated health care delivery and coverage organization.

CHIP

Geisinger Health Plan Kids (GHP Kids) is a Children's Health Insurance Program (CHIP) offered by Geisinger Health Plan in conjunction with the Pennsylvania Department of Human Services (DHS). Geisinger Health Plan is part of Geisinger, an integrated health care delivery and coverage organization.

Medicaid

Geisinger Health Plan Family (GHP Family) is a Medical Assistance (Medicaid) insurance program offered by Geisinger Health Plan in conjunction with the Pennsylvania Department of Human Services (DHS). Geisinger Health Plan is part of Geisinger, an integrated health care delivery and coverage organization.

V. Additional Definitions

Medical Necessity or Medically Necessary means Covered Services rendered by a Health Care Provider that the Plan determines are:

- a. appropriate for the symptoms and diagnosis or treatment of the Member's condition, illness, disease or injury;
- b. provided for the diagnosis, and the direct care and treatment of the Member's condition, illness disease or injury;
- c. in accordance with current standards of good medical treatment practiced by the general medical community.
- d. not primarily for the convenience of the Member, or the Member's Health Care Provider; and
- e. the most appropriate source or level of service that can safely be provided to the Member. When applied to hospitalization, this further means that the Member requires acute care as an inpatient due to the nature of the services rendered or the Member's condition, and the Member cannot receive safe or adequate care as an outpatient.

Medicaid Business Segment

Medically Necessary — A service, item, procedure, or level of care that is necessary for the proper treatment or management of an illness, injury, or disability is one that:

- Will, or is reasonably expected to, prevent the onset of an illness, condition, injury or disability.
- Will, or is reasonably expected to, reduce or ameliorate the physical, mental or developmental effects of an illness, condition, injury or disability.
- Will assist the Member to achieve or maintain maximum functional capacity in performing daily activities, taking into account both the functional capacity of the Member and those functional capacities that are appropriate for Members of the same age.

Serum Testing for Evidence of Mild Traumatic Brain Injury

Policy Number: AHS – G2151 – Serum Testing for Evidence of Mild Traumatic Brain Injury	Original Effective Date: 01/01/2025 Current Effective Date: 10/15/2025
--	---

[POLICY DESCRIPTION](#) | [RELATED POLICIES](#) | [INDICATIONS AND/OR LIMITATIONS OF COVERAGE](#) | [TABLE OF TERMINOLOGY](#) | [SCIENTIFIC BACKGROUND](#) | [GUIDELINES AND RECOMMENDATIONS](#) | [APPLICABLE STATE AND FEDERAL REGULATIONS](#) | [APPLICABLE CPT/HCPCS PROCEDURE CODES](#) | [EVIDENCE-BASED SCIENTIFIC REFERENCES](#) | [REVISION HISTORY](#)

Policy Description

Traumatic brain injury (TBI) is characterized by pathologic injuries to the brain resulting from external forces or trauma. A broad range of sequela of varying clinical severity include focal contusions and hematomas, diffuse axonal injury, cerebral edema and swelling, and a cascade of molecular injury mechanisms.¹

Concussion refers to the trauma-induced alteration in mental status, which may or may not involve loss of consciousness, after a mild TBI.² Measurement of blood and other fluid biomarkers has been proposed as a way of evaluating mild traumatic brain injury.

Related Policies

Policy Number	Policy Title
N/A	Not applicable

Indications and/or Limitations of Coverage

Application of coverage criteria is dependent upon an individual’s benefit coverage at the time of the request. Specifications pertaining to Medicare and Medicaid can be found in the “Applicable State and Federal Regulations” section of this policy document.

The following does not meet coverage criteria due to a lack of available published scientific literature confirming that the test(s) is/are required and beneficial for the diagnosis and treatment of an individual's illness.

- 1) For the evaluation of mild traumatic brain injury (TBI), measurement of concussion markers (e.g., S100B, GFAP, and UCH-L1) in the blood, saliva, and/or cerebrospinal fluid (CSF) **DOES NOT MEET COVERAGE CRITERIA.**
- 2) Panels designed to measure biomarkers of TBI (e.g., i-STAT TBI Plasma, Alinity® i TBI) **DO NOT MEET COVERAGE CRITERIA.**

Table of Terminology

Term	Definition
AAFP	American Academy of Family Physicians
AAOS	American Academy of Orthopedic Surgeons
AAP	American Academy of Pediatrics
ACEP	American College of Emergency Physicians
ACSM	American College of Sports Medicine
AMPA	α -Amino-3-Hydroxy-5- Methyl-4-Isoxazolepropionic Acid Receptor
AMSSM	American Medical Society for Sports Medicine
AOASM	American Osteopathic Academy of Sports Medicine
AOSSM	American Orthopedic Society for Sports Medicine
AUC	Areas under the curve
BTI™	Brain trauma indicator
CDC	Centers for Disease Control
CISG	Concussion In Sport Group
CLIA '88	Clinical Laboratory Improvement Amendments Of 1988
CMS	Centers for Medicare and Medicaid
CNS	Central nervous system
CPT	Current procedural terminology
CSF	Cerebrospinal fluid
CT	Computed tomography
EEG	Electroencephalogram
ELISA	Enzyme-Linked Immunosorbent Assay
FDA	Food and Drug Administration
GFAP	Glial fibrillary acidic protein
GFAP-BDP	Glial fibrillary acidic protein breakdown products
GOS	Glasgow outcome score
HCPCS	Healthcare Common Procedure Coding System
JAMA	Journal of the American Medical Association
LDTs	Laboratory-developed tests
MMP-9	Matrix metalloproteinase 9
MMWR	Morbidity and Mortality Weekly Report
MRI	Magnetic resonance imaging
mTBI	Mild traumatic brain injury
NICE	National Institute of Care and Excellence
NSE	Neuron-specific enolase
ONF	Ontario Neurotrauma Foundation
S100B	S100 calcium-binding protein b

SRC	Sport-related concussion
sTBI	Severe traumatic brain injury
TBI	Traumatic brain injury
UCH-L1	Ubiquitin C-terminal hydrolase-11
VA/DoD	Veterans Administration / Department of Defense

Scientific Background

According to the CDC, there were over 69,000 TBI-related deaths in the United States in 2021.³ Although approximately 75% of TBIs are mild, TBI can adversely affect a person's quality of life in numerous ways, including cognitive functioning, emotional functioning, and physical effects.^{4,5} As many as one in five TBI patients have symptoms persisting past one month.⁶

Accurate diagnosis of TBI is critical to effective management and intervention but can be challenging due to the nonspecific and variable presentation.⁷ Tools available to objectively diagnose injury and prognosticate recovery are limited.⁸ Clinical assessment usually includes a neurological exam, followed by a computed tomography (CT) scan of the head to detect brain tissue damage that may require treatment.⁹ However, as most patients with mild TBI do not have detectable intracranial lesions, like epidural hematomas, on a CT scan², this assessment relies heavily on nonspecific symptoms that can vary widely and ignores the mechanistic heterogeneity of TBI.¹

Brain damage in TBIs is initially caused by external mechanical forces being transferred to intracranial contents, generating shearing and strain forces which stretch and damage axons, and can result in contusions, hematomas, cerebral edema and swelling. Common mechanisms include direct impact, rapid acceleration/deceleration, penetrating injury, and blast waves. However, the pathophysiology of TBI is now understood to include not only the acute event, but also the resulting cascade of molecular injury mechanisms that are initiated at the time of initial trauma and continue for hours or days.¹ The pathophysiology of even mild TBI is complex and may include both focal and diffuse injury patterns. Neuropathological changes found after mild TBI indicate mild multifocal axonal injury, including altered circuit dysfunction and traumatic axonal injury.¹⁰

Cell death and the initiation of local metabolic and inflammatory processes resulting from TBI results in the release of a number of inflammatory mediators and damage-associated molecules that are able to cross a dysfunctional blood-brain barrier¹¹ or enter the circulation through the glymphatic pathway.¹² Neurobiochemical marker levels in blood after TBI may reflect structural changes detected by neuroimaging.⁷ Simpler, sensitive, and specific tests that provide early, quantitative information about the extent of brain tissue damage, identifying and stratifying TBI, would allow rapid and tailored diagnosis of TBI, while minimizing the time, risk, and cost associated with current standards.¹³ No single ideal TBI biomarker exists.¹⁴ However, brain-specific markers of neuronal, glial, and axonal damage, identified in the peripheral blood, have shown potential clinical utility as diagnostic, prognostic, and monitoring adjuncts and have been investigated both individually and in combination.^{11,15} Acute-phase biomarkers, including S100 calcium-binding protein B (S100B), glial fibrillary acidic protein (GFAP), and ubiquitin C-terminal hydrolase-L1 (UCH-L1), have shown potential for use in initial screening of patients presenting with head trauma, the vast majority of whom will have normal brain CT findings.^{2,16}

However, recent reviews have noted concerns about a lack of specificity and unresolved issues with the use of mTBI blood biomarkers. While researchers note “impressive levels of sensitivity,” they simultaneously acknowledge that correlations between blood biomarker levels and mTBI severity have been “disappointing to date.” In particular, they state that it remains inconclusive whether biomarkers can predict recovery time, post-concussion syndrome, and/or return to sports activities.¹⁷

S100 calcium-binding protein B (S100B)

S100 calcium-binding protein B belongs to the calcium binding EF-hand protein group, and it has been associated with cytoskeleton structure, Ca²⁺ homeostasis, cell proliferation, protein phosphorylation and degradation.^{18,19} S100B is expressed in the cytoplasm and the nucleus of astrocytes and is present in the bloodstream when the blood-brain barrier is disrupted. Several studies indicate that S100B measurement, either acutely or at several time points, can distinguish injured from non-injured patient¹⁹ and guidelines intended to reduce the need for CT scan using S100B levels in the blood for the initial management of mild TBI have been published.²⁰ These guidelines were recently validated in a large multicenter study where S100B was found to have a sensitivity of 97% and a specificity of 34% for the identification of intracranial hemorrhages confirmed by CT scans. The authors estimated CT scans would have been reduced by 32% with application of these guidelines.²¹ However, other investigators have failed to detect associations between S100B with CT abnormalities.²² Additionally, it has limited utility in multiple trauma settings as it is not brain-specific. S100B can be found in non-neural cells, such as adipocytes, chondrocytes, and melanocytes,^{18,23} and its levels are also elevated in trauma, specifically orthopedic, without head injury.^{24,25} However, recent data highlight the inclusion of S100B in sets of markers that in combination could contribute to better diagnosis, monitoring, and treatment of CNS conditions.¹⁸

Glial Fibrillary Acidic Protein (GFAP)

Glial Fibrillary Acidic Protein is a filament protein that maintains cell shape and structure, coordinates cells' mobility and contributes to the transduction of molecular signals in astrocytes. It is released upon cellular disintegration and degradation of the astrocyte. Concentration of serum GFAP increases after neural trauma and TBI, either as the intact protein or as breakdown products.^{18,25} GFAP measurements have provided promising data on injury pathway indication, focal versus diffuse injuries, and prediction of morbidity and mortality.¹⁹ GFAP level was increased in patients with CT-positive scans for intracranial lesions compared to CT-negative scans after mild TBI.²⁶ Sensitivities have been reported between 67% and 100% while the specificities ranged from 0% and 89%.⁷

McMahon et al¹³ performed a multicenter trial to evaluate GFAP and its breakdown product GFAP-BDP in the diagnosis of intracranial injury. They found that "GFAP-BDP demonstrated very good predictive ability (area under the curve=0.87) and demonstrated significant discrimination of injury severity (odds ratio, 1.45; 95% confidence interval, 1.29-1.64)." The authors concluded that "use of GFAP-BDP yielded a net benefit above clinical screening alone and a net reduction in unnecessary scans by 12-30%."¹³

Ubiquitin C-terminal Hydrolase-L1 protein (UCH-L1)

Ubiquitin C-terminal Hydrolase-L1 protein is a cytoplasmic enzyme, highly enriched and specifically expressed in neurons, involved in the ubiquitinylation of abnormal proteins destined for proteasomal degradation.¹⁴ It is also an important element of axonal transport and, by a strong interaction with cytoskeleton proteins, plays an important role in the axon's integrity.¹⁸ UCH-L1 has been shown to increase after TBI in serum and CSF as well as correlate with TBI severity and abnormal CT findings.^{25,27} UCH-L1 has also been shown to be significantly elevated in serum among athletes after concussions.²⁵ High prognostic value of poor outcome was found at both 3-months²⁷ and 6-months intervals.²⁸ Two recent studies report the same sensitivity of 100% and specificities of 21% and 39%.⁷

Clinical Utility and Validity

Welch, et al. (2016) evaluated three serum biomarkers' (GFAP, ubiquitin C-terminal hydrolase-L1 [UCH-L1] and S100B measured within 6 h of injury) ability to differentiate CT-negative and CT-positive findings. They found that "UCH-L1 was 100% sensitive and 39% specific at a cutoff value >40 pg/mL. To retain 100% sensitivity, GFAP was 0% specific (cutoff value 0 pg/mL) and S100B had a specificity of only 2% (cutoff value 30 pg/mL). All three biomarkers had similar values for areas under the receiver operator characteristic curve:

0.79 for GFAP, 0.80 for UCH-L1, and 0.75 for S100B. Neither GFAP nor UCH-L1 curve values differed significantly from S100B. In our patient cohort, UCH-L1 outperformed GFAP and S100B when the goal was to reduce CT use without sacrificing sensitivity. UCH-L1 values <40 pg/mL could potentially have aided in eliminating 83 of the 215 negative CT scans.”²⁹ However, the authors note that further research is needed.

Wang, et al. (2018) reported on the usage of TBI serum and CSF biomarkers as prognostic tools in the ED, neurointensive care unit, and out-of-hospital settings. In the case of mTBI, the researchers stated the similar biomarkers could aid in predicting any development of persistent post-concussive syndrome, including S100B, GFAP, and UCH-L1. Within 12-36 hours from TBI in neurointensive care units, it was found that serum levels of 100B correlate with patient outcomes, and S100B serum levels > 0.7ng/mL correlate with 100% mortality. GFAP modestly correlates with poor outcomes, and “serum GFAP levels were also significantly higher in patients who died or had an unfavorable outcome and have predicted neurological outcome at 6 months.” It was also shown in other studies that GFAP and UCHL-1 proteins outperformed S100B in predicting poor outcomes, and the two together “predicate the recovery and unfavorable outcome by distinguishing patients with GOS [Glasgow Outcome Score] 1-3 from patients with GOS 4-5.”^{25,30,31}

Gan, et al. (2019) evaluated TBI serum biomarkers for four clinical situations: “detecting concussion, predicting intracranial damage after mild TBI (mTBI), predicting delayed recovery after mTBI, and predicting adverse outcome after severe TBI (sTBI).” A total of 200 publications (61722 “observations”) were included. For concussion detection, nine unique publications addressing 15 biomarkers and 946 observations were identified. Four panels (“copeptin, galectin-3, and MMP-9; GFAP and UCH-L1; 10 metabolites; and 17 metabolites”) were found to have areas under the curve (AUC) of over 0.9. For evaluation of necessity of CT scan after TBI, 56 publications, 24 biomarkers, and 23316 observations were identified. S-100B (30 publications, 8464 observations) was found to have an AUC of 0.723 and GFAP/GFAP-BDP (16 publications, 2040 observations) was found to have an AUC of 0.831. For evaluation of delayed recovery after mTBI, 44 publications, 29 biomarkers, and 13291 observations were identified. S-100B (24 publications, 2800 observations) had an AUC of 0.691; GFAP’s AUC was 0.716 (17 publications, 1959 observations). Finally, for evaluation of poor outcome after sTBI, S-100B (25 publications, 3712 observations) was rated at AUC of 0.762, and GFAP (10 publications, 2448 observations) was rated at AUC of 0.749. Neuron-specific enolase (9 publications, 911 observations) was rated at AUC of 0.715.³²

Korley, et al. (2022) investigated the prognostic value of GFAP and ubiquitin C-terminal hydrolase L1 (UCH-L1) in traumatic brain injuries in a study called TRACK-BTI. The prognostic accuracy of the two biomarkers was studied amongst 2552 participants. Participants were 17 years and older and had been evaluated for TBI. All patients were given a head CT during evaluation. Participants had plasma samples taken on the day of injury (for measurement of GFAP and UCH-L1). In the results, of the 1696 participants with brain injury (data available at baseline and at six months), 120 (7.1%) died, 235 (13.9%) had unfavorable outcomes, and 561 (33.1%) recovered fully. The area under the curve of GFAP for predicting death at six months in all patients was .87 (95% CI 0.83-0.91), for unfavorable outcome was 0.86 (0.83-0.89), and for incomplete recovery was 0.62 (0.59-0.64). The AUC for UCH-L1 was 0.89 (95% CI 0.86-0.92) for prediction of death, 0.86 (0.84-0.89) for unfavorable outcome, and 0.61 (0.59-0.64) for incomplete recovery at six months. Additionally, “Among participants with GCS [Glasgow Coma Scale] score of 3–12 (n=353), adding GFAP and UCH-L1 (alone or combined) to each of the three International Mission for Prognosis and Analysis of Clinical Trials in traumatic brain injury models significantly increased their AUCs for predicting death (AUC range 0.90–0.94) and unfavourable outcome (AUC range 0.83–0.89). The authors concluded, “GFAP and UCH-L1 plasma concentrations have good to excellent prognostic value for predicting death and unfavourable outcome, but not for predicting incomplete recovery at 6 months.”³³

In January 2021, Abbott Laboratories received FDA 510(K) clearance for the i-STAT™ Alinity™ handheld device, which would help evaluate mTBIs. It simultaneously measures UCH-L1 and GFAP in blood and produces results in 15 minutes once a plasma sample is inserted. It has a sensitivity of 95.8% and a >99% negative predictive value. Abbott Laboratories states that this blood test’s availability “could help eliminate wait

time in the emergency room and could reduce the number of unnecessary CT scans by up to 40%.” The company is also working on a whole blood test, and has received breakthrough designation to create a TBI test that runs “on its Alinity™ and ARCHITECT® core laboratory instruments.”³⁴

In March 2023, Abbott Laboratories received FDA clearance for the Alinity® i TBI test that measures two biomarkers in the blood— C-terminal hydrolase L1 (UCH-L1) and GFAP. Like the i-STAT™ Alinity™, this test is intended for use in adults who are suspected of having mild TBI, such as adults who present to the hospital within 12-hours of a concussion or suspected mTBI. Initial studies show the test provides results with 96.7% sensitivity and 99.4% negative predictive value. After a blood draw, results are available within 18 minutes and the test is run on Abbott’s Alinity™ i platform.³⁵

Guidelines and Recommendations

American College of Emergency Physicians (ACEP)

The ACEP recommended consideration could be given to not performing a CT (Level C) in mild TBI patients without significant extracranial injuries and a serum S100β of level less than 0.1μg/L measured within 4 h of injury.³⁶

In their 2023 clinical policy entitled, “Critical Issues in the Management of Adult Patients Presenting to the Emergency Department with Mild Traumatic Brain Injury,” the ACEP acknowledges, “Perhaps there are some CT scans performed in [patients with mTBI] that are unnecessary. Serum biomarkers, such as S-100 calcium-binding protein or brain-specific glial fibrillary acidic protein, may add information. The addition of biomarker information may then be combined with patient history and examination features or components of existing clinical tools, with the potential for increased specificity and decreased CT utilization. However, at this point, strong data on biomarker use with or without other decision tools is lacking and limited by the availability of these tests.”³⁷

Centers for Disease Control

The CDC reaffirmed the 2008 ACEP recommendation in 2016.³⁸ However, in 2018, the CDC remarked that “Health care professionals should not use biomarkers outside of a research setting for the diagnosis of children with mTBI,” noting that there is insufficient evidence to recommend any of the studied biomarkers for mTBI diagnosis in children. The CDC identified S100B, tau protein, autoantibodies against glutamate receptors and oxide metabolites, neuronal ubiquitin C-terminal hydrolase-L1, and glial fibrillary acidic protein biomarker levels as biomarkers that have been studied for concussion evaluation.³⁹

The Veterans Administration and Department of Defense

The Veterans Administration and Department of Defense Practice Guideline for the Management of Concussion – mild Traumatic Brain Injury states that:

“Excluding patients with indicators for immediate referral, for patients identified by post-deployment screening or who present to care with symptoms or complaints potentially related to brain injury, we suggest *against* using the following tests to establish the diagnosis of mTBI or direct the care of patients with a history of mTBI:

- a. Neuroimaging
- b. Serum biomarkers, including S100 calcium-binding protein B (S100-B), glial fibrillary acidic protein (GFAP), ubiquitin carboxyl-terminal esterase L1 (UCH-L1), neuron specific enolase (NSE), and α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor (AMPA) peptide
- c. Electroencephalogram (EEG).”⁴⁰

American College of Sports Medicine (ACSM), American Academy of Family Physicians (AAFP), American Academy of Orthopedic Surgeons (AAOS), American Medical Society for Sports Medicine (AMSSM), American Orthopedic Society for Sports Medicine (AOSSM), and the American Osteopathic Academy of Sports Medicine (AOASM)

A joint consensus statement states that: “Investigation in the area of biomarkers (e.g., S-100 proteins, neuron specific enolase, tau protein) is inconclusive for identifying individuals with concussion and represents research that may one day be clinically applicable.”⁴¹

American Medical Society for Sports Medicine

The American Medical Society for Sports Medicine notes that fluid biomarkers (blood, saliva, and cerebrospinal fluid) in diagnosis of sports-related concussion are under active investigation, but states that overall evidence level is “low.” The Society writes that more studies are needed to determine their clinical utility. The Society also acknowledges the FDA approval of the “two-protein brain trauma indicator with glial fibrillary acidic protein and ubiquitin carboxy-terminal hydrolase L1 (UCHL1), and clinical use of S100 calcium-binding protein b (s100b) in Europe,” but remark that neither of these tests have a role in diagnosis or management of a sports-related concussion.⁴²

American Academy of Pediatrics (AAP)

The AAP acknowledges that biomarkers such as “S100 β , glial fibrillary acidic protein, neuron-specific enolase, τ , neurofilament light protein, amyloid β , brain-derived neurotrophic factor, creatine kinase and heart-type fatty acid binding protein, prolactin, cortisol, and albumin” have all been investigated in concussion evaluation, but none of these biomarkers have been used in clinical settings.^{43,44}

6th International Consensus Conference on Concussion in Sport

The 6th International Consensus Conference on Concussion in Sport released the Amsterdam Consensus Statement in December 2023. With regards to serum biomarkers, the group stated, “when compared with adults, the influences of puberty and brain development in children and adolescents may result in differences in the performance and utility of fluid biomarkers and emerging technologies for the purpose of diagnosing SRC and assessing neurobiological recovery.” At the individual level, “their role in guiding clinical management...remains unclear.”⁴⁵

National Institute for Health and Care Excellence (NICE)

The NICE guidelines regarding “assessment and early management of head injury in children, young people and adults” do not mention any serum biomarkers for evaluation of head injuries.⁴⁶

American Congress of Rehabilitation Medicine Brain Injury Interdisciplinary Special Interest Group Mild TBI Task Force

The American Congress of Rehabilitation Medicine Brain Injury Interdisciplinary Special Interest Group Mild TBI Task Force published a synthesis of practice guidelines for “Management of Concussion and Mild Traumatic Brain Injury.” In it, they note that the Scandinavian Neurotrauma Committee guidelines recommend that “S100B values of <0.10 mg/L, if sampled within 6 hours of injury, can help rule out the need for CT in patients younger than 65 years with a Glasgow Coma Scale score of 14 or a Glasgow Coma Scale score of 15 with loss of consciousness or repeated vomiting.” However, they also remark that neither GFAP nor C-terminal hydrolase-L1 have been incorporated into any published clinical practice guidelines. Further, the task force notes that the biomarkers’ incremental value over established clinical decision rules (such as the Canadian CT head rule) is unknown.

The task force also states that “At present, there is no objective biomarker to determine mTBI resolution.”⁶

International Traumatic Brain Injury Research (InTBIR) Initiative

The InTBIR Initiative states that there “remains a critical need for more accurate diagnostic and prognostic tools in TBI. The development and validation of genomic, proteomic, and imaging biomarkers will be essential for tackling TBI heterogeneity and moving towards precision medicine. The heterogeneous nature of traumatic brain injury presents a major challenge to biomarker identification, validation, and clinical application.”

In a statement on genomic screening, they note that a genome-scale wide approach hasn’t gained traction over identifying single candidate biomarkers, and that “regardless of the method by which a candidate biomarker is identified, appropriate testing and validation is crucial to accurately assess a biomarker’s predictive/diagnostic potential.”

Regarding specific biomarkers, they state, “Proteins highly specific to astroglial overexpression and injury, S100B and glial fibrillary acidic protein (GFAP) are logical choices for investigation. S100B is a calcium-

binding protein found in astrocytes, the levels of which are elevated in response to neural injury or inflammation. A number of clinical studies have shown that elevated serum levels of S100B correlate with poor outcome after TBI, but S100B has also been shown to be elevated in response to other inflammatory/traumatic processes in the absence of TBI.” Furthermore, “In the case of S100B, although it has been shown to be highly sensitive to brain trauma, it lacks specificity for TBI because it is also released from extracerebral tissue and can be elevated in response to numerous other non-CNS injuries.”

Regarding GFAP, they note it has been “suggested that it may serve as a marker of focal lesions and intracranial bleeding but may not be adequately sensitive to axonal injury. Unlike GFAP, the protease ubiquitin C-terminal hydrolase-L1 (UCH-L1) has been shown to be suggestive of diffuse injuries and appears to be a promising TBI biomarker candidate in its own right. Taken together, these observations suggest that simultaneous assessment of biomarkers reflecting different pathophysiological mechanisms and injury types would provide complementary information and might increase diagnostic and prognostic accuracy, hence enabling clinicians to stratify risk more effectively among TBI patients.”⁴⁷

American College of Surgeons

The American College of Surgeons introduced guidance on blood-based biomarker testing on brain injuries. Brain injury biomarkers such as “glial fibrillary acidic protein (GFAP), ubiquitin carboxy-terminal hydrolase L1 (UCH-L1), and S100 calcium-binding protein (S100B) can be used to rule out the need for brain CT imaging for individuals with suspected TBI who meet the following; Glasgow Coma Scale of 13–15, Clinical criteria for brain CT imaging based on brain CT imaging decision rules, and the clinician assesses a low but nonzero risk for traumatic ICH. The extent of GFAP, UCH-L1, and S100B elevation on the day of injury provides clinicians with an estimate of the underlying structural brain injury severity. These blood levels are also useful as adjuncts for predicting functional recovery at six months postinjury in individuals with GCS 3–12 associated with TBI. Two blood-based protein biomarkers, GFAP and UCH-L1, can be measured in individuals (18 years or older) with a potential TBI to help rule out the need for a brain CT scan. Individuals with Alzheimer’s disease and related dementias have higher baseline levels of brain injury biomarkers, including GFAP and UCH-L1. There is insufficient data regarding the utility of GFAP, UCH-L1, and S100B on pediatric individuals.”⁴⁸

Applicable State and Federal Regulations

DISCLAIMER: If there is a conflict between this policy and any relevant, applicable government policy for a particular member [e.g., Local Coverage Determinations (LCDs) or National Coverage Determinations (NCDs) for Medicare and/or state coverage for Medicaid], then the government policy will be used to make the determination. For the most up-to-date Medicare policies and coverage, please visit the Medicare search website: <http://www.cms.gov/medicare-coverage-database/overview-and-quick-search.aspx>. For the most up-to-date Medicaid policies and coverage, visit the applicable state Medicaid website.

Food and Drug Administration (FDA)

Many labs have developed specific tests that they must validate and perform in house. These laboratory-developed tests (LDTs) are regulated by the Centers for Medicare and Medicaid (CMS) as high-complexity tests under the Clinical Laboratory Improvement Amendments of 1988 (CLIA '88). LDTs are not approved or cleared by the U. S. Food and Drug Administration; however, FDA clearance or approval is not currently required for clinical use.

On Jan 8, 2021, with 510(K) clearance, the FDA approved marketing of i-STAT TBI Plasma Cartridge with the i-STAT™ Alinity™ System from Abbott Laboratories. This brain trauma assessment test is intended for *in vitro* diagnostic use to aid in evaluating patients, 18 years of age or older, with suspected mTBI (Glasgow Coma Scale score 13-15) within 12 hours of injury with other clinical information to assess the need for radiologic imaging (CT, MRI). A result from this test is associated with the absence or presence of acute traumatic intracranial lesions seen on a head CT scan, but is not intended for use in point of care settings.⁴⁹ In March 2023, the FDA

approved Abbott’s Alinity® i TBI lab test as a complement to the i-STAT™ Alinity™ System. According to Abbott, the test measures ubiquitin C-terminal hydrolase L1 (UCH-L1) and GFAP; the test assesses whether there are elevated concentrations of these biomarkers in the blood. While the i-STAT™ Alinity™ System is the first rapid hand-held test that measures biomarkers in plasma, the Alinity® i TBI test is a blood test run on Abbott’s Alinity® i instrument.³⁵

Applicable CPT/HCPCS Procedure Codes

CPT	Code Description
83516	Immunoassay for analyte other than infectious agent antibody or infectious agent antigen; qualitative or semiquantitative, multiple step method
84999	Unlisted chemistry procedure
0570U	Neurology (traumatic brain injury), analysis of glial fibrillary acidic protein (GFAP) and ubiquitin carboxylterminal hydrolase L1 (UCHL1), immunoassay, whole blood or plasma, individual components reported with the overall result of elevated or non-elevated based on threshold comparison Proprietary test: i-STAT TBI Lab/Manufacturer: Abbott Point of Care

Current Procedural Terminology[®] American Medical Association. All Rights reserved.
Procedure codes appearing in Medical Policy documents are included only as a general reference tool for each policy. They may not be all-inclusive.

Evidence-based Scientific References

1. Williamson C, Rajajee V. Traumatic brain injury: Epidemiology, classification, and pathophysiology. Updated May 16, 2023. <https://www.uptodate.com/contents/traumatic-brain-injury-epidemiology-classification-and-pathophysiology>
2. Evans RW, Whitlow CT. Acute mild traumatic brain injury (concussion) in adults. Updated November 13, 2024. <https://www.uptodate.com/contents/acute-mild-traumatic-brain-injury-concussion-in-adults>
3. CDC. Traumatic Brain Injury and Concussion. <https://www.cdc.gov/traumatic-brain-injury/data-research/facts-stats/>
4. Report to Congress on Traumatic Brain Injury Epidemiology and Rehabilitation | Concussion | Traumatic Brain Injury | CDC Injury Center (Centers for Disease Control and Prevention.) (2015).
5. Wright DW, Kellermann A, McGuire LC, Chen B, Popovic T. CDC Grand Rounds: Reducing Severe Traumatic Brain Injury in the United States. *MMWR Morb Mortal Wkly Rep.* 2013;62(27):549-52.
6. Silverberg ND, Iaccarino MA, Panenka WJ, et al. Management of Concussion and Mild Traumatic Brain Injury: A Synthesis of Practice Guidelines. *Arch Phys Med Rehabil.* Feb 2020;101(2):382-393. doi:10.1016/j.apmr.2019.10.179
7. Mondello S, Sorinola A, Czeiter E, et al. Blood-Based Protein Biomarkers for the Management of Traumatic Brain Injuries in Adults Presenting with Mild Head Injury to Emergency Departments: A Living Systematic Review and Meta-Analysis. *Journal of neurotrauma.* Oct 12 2021;doi:10.1089/neu.2017.5182
8. Mannix R, Eisenberg M, Berry M, Meehan WP, 3rd, Hayes RL. Serum biomarkers predict acute symptom burden in children after concussion: a preliminary study. *Journal of neurotrauma.* Jun 1 2014;31(11):1072-5. doi:10.1089/neu.2013.3265
9. FDA authorizes marketing of first blood test to aid in the evaluation of concussion in adults. WebContent. U.S. Food and Drug Administration; 2018. <https://www.fda.gov/newsevents/newsroom/pressannouncements/ucm596531.htm>
10. Truettner JS, Bramlett HM, Dietrich WD. Hyperthermia and Mild Traumatic Brain Injury: Effects on Inflammation and the Cerebral Vasculature. *Journal of neurotrauma.* Feb 9 2018;doi:10.1089/neu.2017.5303

11. Di Battista AP, Buonora JE, Rhind SG, et al. Blood Biomarkers in Moderate-To-Severe Traumatic Brain Injury: Potential Utility of a Multi-Marker Approach in Characterizing Outcome. *Front Neurol.* 2015;6doi:10.3389/fneur.2015.00110
12. Plog BA, Dashnaw ML, Hitomi E, et al. Biomarkers of traumatic injury are transported from brain to blood via the glymphatic system. *The Journal of neuroscience : the official journal of the Society for Neuroscience.* Jan 14 2015;35(2):518-26. doi:10.1523/jneurosci.3742-14.2015
13. McMahon PJ, Panczykowski DM, Yue JK, et al. Measurement of the Glial Fibrillary Acidic Protein and Its Breakdown Products GFAP-BDP Biomarker for the Detection of Traumatic Brain Injury Compared to Computed Tomography and Magnetic Resonance Imaging. *Journal of neurotrauma.* 2015:527-33. vol. 8.
14. Halford J, Shen S, Itamura K, et al. New astroglial injury-defined biomarkers for neurotrauma assessment. *Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.* Oct 2017;37(10):3278-3299. doi:10.1177/0271678x17724681
15. Mondello S, Jeromin A, Buki A, et al. Glial neuronal ratio: a novel index for differentiating injury type in patients with severe traumatic brain injury. *Journal of neurotrauma.* Apr 10 2012;29(6):1096-104. doi:10.1089/neu.2011.2092
16. Maas AIR, Menon DK, Adelson PD, et al. Traumatic brain injury: integrated approaches to improve prevention, clinical care, and research. *The Lancet Neurology.* Dec 2017;16(12):987-1048. doi:10.1016/s1474-4422(17)30371-x
17. Hier DB, Obafemi-Ajayi T, Thimman MS, et al. Blood biomarkers for mild traumatic brain injury: a selective review of unresolved issues. *Biomarker Research.* 2021/09/16 2021;9(1):70. doi:10.1186/s40364-021-00325-5
18. Chmielewska N, Szyndler J, Makowska K, Wojtyna D, Maciejak P, Plaznik A. Looking for novel, brain-derived, peripheral biomarkers of neurological disorders. *Neurologia i neurochirurgia polska.* Feb 13 2018;doi:10.1016/j.pjnns.2018.02.002
19. Strathmann FG, Schulte S, Goerl K, Petron DJ. Blood-based biomarkers for traumatic brain injury: evaluation of research approaches, available methods and potential utility from the clinician and clinical laboratory perspectives. *Clinical biochemistry.* Jul 2014;47(10-11):876-88. doi:10.1016/j.clinbiochem.2014.01.028
20. Ingebrigtsen T, Romner B, Kock-Jensen C. Scandinavian guidelines for initial management of minimal, mild, and moderate head injuries. The Scandinavian Neurotrauma Committee. *The Journal of trauma.* Apr 2000;48(4):760-6.
21. Uden L, Calcagnile O, Uden J, Reinstrup P, Bazarian J. Validation of the Scandinavian guidelines for initial management of minimal, mild and moderate traumatic brain injury in adults. *BMC medicine.* Dec 9 2015;13:292. doi:10.1186/s12916-015-0533-y
22. Piazza O, Storti MP, Cotena S, et al. S100B is not a reliable prognostic index in paediatric TBI. *Pediatric neurosurgery.* 2007;43(4):258-64. doi:10.1159/000103304
23. Papa L, Silvestri S, Brophy GM, et al. GFAP Out-Performs S100 β in Detecting Traumatic Intracranial Lesions on Computed Tomography in Trauma Patients with Mild Traumatic Brain Injury and Those with Extracranial Lesions. *Journal of neurotrauma.* 2014;31(22):1815-22. doi:10.1089/neu.2013.3245
24. Anderson RE, Hansson LO, Nilsson O, Dijlai-Merzoug R, Settergren G. High serum S100B levels for trauma patients without head injuries. *Neurosurgery.* Jun 2001;48(6):1255-8; discussion 1258-60.
25. Wang KK, Yang Z, Zhu T, et al. An update on diagnostic and prognostic biomarkers for traumatic brain injury. *Expert Rev Mol Diagn.* 2018;18(2):165-180. doi:10.1080/14737159.2018.1428089
26. Lei J, Gao G, Feng J, et al. Glial fibrillary acidic protein as a biomarker in severe traumatic brain injury patients: a prospective cohort study. *Critical care (London, England).* Oct 12 2015;19:362. doi:10.1186/s13054-015-1081-8
27. Diaz-Arrastia R, Wang KK, Papa L, et al. Acute Biomarkers of Traumatic Brain Injury: Relationship between Plasma Levels of Ubiquitin C-Terminal Hydrolase-L1 and Glial Fibrillary Acidic Protein. *Journal of neurotrauma.* 2014:19-25. vol. 1.
28. Mondello S, Akinyi L, Buki A, et al. Clinical Utility of Serum Levels of Ubiquitin C-Terminal Hydrolase as a Biomarker for Severe Traumatic Brain Injury. *Neurosurgery.* Mar 2012;70(3):666-75. doi:10.1227/NEU.0b013e318236a809

29. Welch RD, Ayaz SI, Lewis LM, et al. Ability of Serum Glial Fibrillary Acidic Protein, Ubiquitin C-Terminal Hydrolase-L1, and S100B To Differentiate Normal and Abnormal Head Computed Tomography Findings in Patients with Suspected Mild or Moderate Traumatic Brain Injury. *Journal of neurotrauma*. Jan 15 2016;33(2):203-14. doi:10.1089/neu.2015.4149
30. Mondello S, Kobeissy F, Vestri A, Hayes RL, Kochanek PM, Berger RP. Serum Concentrations of Ubiquitin C-Terminal Hydrolase-L1 and Glial Fibrillary Acidic Protein after Pediatric Traumatic Brain Injury. *Sci Rep*. Jun 20 2016;6:28203. doi:10.1038/srep28203
31. Takala RS, Posti JP, Runtti H, et al. Glial Fibrillary Acidic Protein and Ubiquitin C-Terminal Hydrolase-L1 as Outcome Predictors in Traumatic Brain Injury. *World Neurosurg*. Mar 2016;87:8-20. doi:10.1016/j.wneu.2015.10.066
32. Gan ZS, Stein SC, Swanson R, et al. Blood Biomarkers for Traumatic Brain Injury: A Quantitative Assessment of Diagnostic and Prognostic Accuracy. *Front Neurol*. 2019;10:446. doi:10.3389/fneur.2019.00446
33. Korley FK, Jain S, Sun X, et al. Prognostic value of day-of-injury plasma GFAP and UCH-L1 concentrations for predicting functional recovery after traumatic brain injury in patients from the US TRACK-TBI cohort: an observational cohort study. *The Lancet Neurology*. 2022;21(9):803-813. doi:10.1016/S1474-4422(22)00256-3
34. Abbott Receives FDA 510(K) Clearance for the First Rapid Handheld Blood Test for Concussions. January 11, 2021, 2021. <https://abbott.mediaroom.com/2021-01-11-Abbott-Receives-FDA-510-k-Clearance-for-the-First-Rapid-Handheld-Blood-Test-for-Concussions>
35. MPR. FDA Clears Lab-Based Blood Test to Aid in Concussion Assessment. Updated March 8, 2023. <https://www.empr.com/home/news/fda-clears-lab-based-blood-test-to-aid-in-concussion-assessment/>
36. Jagoda AS, Bazarian JJ, Bruns JJ, et al. Clinical Policy: Neuroimaging and Decisionmaking in Adult Mild Traumatic Brain Injury in the Acute Setting. *Journal of Emergency Nursing*. 2009/03/01/ 2009;35(2):e5-e40.
37. Valente JH, Anderson JD, Paolo WF, et al. Clinical Policy: Critical Issues in the Management of Adult Patients Presenting to the Emergency Department With Mild Traumatic Brain Injury: Approved by ACEP Board of Directors, February 1, 2023 Clinical Policy Endorsed by the Emergency Nurses Association (April 5, 2023). *Ann Emerg Med*. May 2023;81(5):e63-e105. doi:10.1016/j.annemergmed.2023.01.014
38. CDC. Mild TBI Management Guideline. https://www.cdc.gov/traumatic-brain-injury/media/pdfs/2018-mTBI_AtAGlance_Diagnosis-508.pdf
39. Lumba-Brown A, Yeates KO, Sarmiento K, et al. Centers for Disease Control and Prevention Guideline on the Diagnosis and Management of Mild Traumatic Brain Injury Among Children. *JAMA Pediatr*. Nov 1 2018;172(11):e182853. doi:10.1001/jamapediatrics.2018.2853
40. VA/DoD clinical practice guidelines for the management of post-acute mild traumatic brain injury. Version 3.0 (Management of Concussion-mild Traumatic Brain Injury Working Group) 133 (2021).
41. Herring SA, Cantu RC, Guskiewicz KM, et al. Concussion (mild traumatic brain injury) and the team physician: a consensus statement--2011 update. *Medicine and science in sports and exercise*. Dec 2011;43(12):2412-22. doi:10.1249/MSS.0b013e3182342e64
42. Harmon KG, Clugston JR, Dec K, et al. American Medical Society for Sports Medicine Position Statement on Concussion in Sport. *Clin J Sport Med*. Mar 2019;29(2):87-100. doi:10.1097/jsm.0000000000000720
43. AAP. Sport-Related Concussion in Children and Adolescents. <http://pediatrics.aappublications.org/content/pediatrics/142/6/e20183074.full.pdf>
44. Halstead ME, Walter KD, Moffatt K. Sport-Related Concussion in Children and Adolescents. *Pediatrics*. 2018;142(6):e20183074. doi:10.1542/peds.2018-3074
45. Davis GA, Schneider KJ, Anderson V, et al. Pediatric Sport-Related Concussion: Recommendations From the Amsterdam Consensus Statement 2023. *Pediatrics*. 2023;153(1):e2023063489. doi:10.1542/peds.2023-063489
46. NICE. Head injury: assessment and early management. Updated May 18, 2023. <https://www.nice.org.uk/guidance/ng232>

47. Huie JR, Mondello S, Lindsell CJ, et al. Biomarkers for Traumatic Brain Injury: Data Standards and Statistical Considerations. *Journal of neurotrauma*. Sep 15 2021;38(18):2514-2529. doi:10.1089/neu.2019.6762
48. American College of Surgeons. Best Practices Guidelines: The Management of Traumatic Brain Injury. <https://www.facs.org/media/vgfgjpfk/best-practices-guidelines-traumatic-brain-injury.pdf>
49. FDA. I-STAT TBI Plasma Cartridge With The I-STAT Alinity System. Updated May 24, 2022. https://www.accessdata.fda.gov/cdrh_docs/pdf20/K201778.pdf

Revision History

Effective Date	Summary
10/15/2025	Reviewed and Updated: Updated the background, guidelines and recommendations, and evidence-based scientific references. Literature review did not necessitate any modifications to coverage criteria. The following changes were made for clarity and consistency: Panel testing moved from CC1 into new CC2 for clarity. New CC2 now reads: “2) Panels designed to measure biomarkers of TBI (e.g., i-STAT TBI Plasma, Alinity® i TBI) DO NOT MEET COVERAGE CRITERIA.” Added CPT code 0570U (effective date 7/1/2025)
01/01/2025	Initial Policy Reconciliation

Medicaid Business Segment:

Any requests for services, that do not meet criteria set in the PARP, may be evaluated on a case by case basis.

LINE OF BUSINESS:

Eligibility and contract specific benefits, limitations and/or exclusions will apply. Coverage statements found in the line of business specific benefit document will supersede this policy. For Medicare, applicable LCD’s and NCD’s will supercede this policy. For PA Medicaid Business segment, this policy applies as written.

Geisinger Health Plan may refer collectively to health care coverage sponsors Geisinger Health Plan, Geisinger Quality Options, Inc., and Geisinger Indemnity Insurance Company, unless otherwise noted. Geisinger Health Plan is part of Geisinger, an integrated health care delivery and coverage organization.

Coverage for experimental or investigational treatments, services and procedures is specifically excluded under the member's certificate with Geisinger Health Plan. Unproven services outside of an approved clinical trial are also specifically excluded under the member's certificate with Geisinger Health Plan. This policy does not expand coverage to services or items specifically excluded from coverage in the member's certificate with Geisinger Health Plan. Additional information can be found in MP015 Experimental, Investigational or Unproven Services.

Prior authorization and/or pre-certification requirements for services or items may apply. Pre-certification lists may be found in the member's contract specific benefit document. Prior authorization requirements can be found at <https://www.geisinger.org/health-plan/providers/ghp-clinical-policies>

Please be advised that the use of the logos, service marks or names of Geisinger Health Plan, Geisinger Quality Options, Inc. and Geisinger Indemnity Insurance Company on a marketing, press releases or any communication piece regarding the contents of this medical policy is strictly prohibited without the prior written consent of Geisinger Health Plan. Additionally, the above medical policy does not confer any endorsement by Geisinger Health Plan, Geisinger Quality Options, Inc. and Geisinger Indemnity Insurance Company regarding the medical service, medical device or medical lab test described under this medical policy.